Trial Profile
A randomized comparative phase 2 study : Palonosetron single-dose versus repeated-dose for prevention of nausea and vomiting induced by multiple-day high or moderate emetic risk chemotherapy in patients with haematological malignancies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 26 Nov 2013 New trial record